Comment on 'effects of locally applied water-filtered infrared a irradiation adjunctive to iloprost and carbon dioxide hand baths in patients with systemic sclerosis and severe Raynaud's phenomenon - a randomized controlled trial'.
Pharmacological targeting of the TLR8/AP-1 axis ameliorates scleroderma skin inflammation and fibrosis by suppressing monocyte-mediated endothelial injury.
Toll-like receptor 8 (TLR8) is implicated in systemic sclerosis (SSc) pathogenesis, but its precise cellular mechanisms remain elusive. This study elucidates TLR8's role in monocyte-endothelial crosstalk and evaluates the therapeutic potential of targeting the TLR8/AP-1 axis in SSc. TLR expression i…
Nailfold Videocapillaroscopy in Pediatric Rheumatology: Established Roles, Emerging Applications, and Future Perspectives.
Nailfold videocapillaroscopy (NVC) provides direct, non-invasive access to the peripheral microcirculation and has become a central tool in adult rheumatology. Its primary clinical value lies in the evaluation of patients presenting with signs of Raynaud phenomenon (RP) and scleroderma-spectrum diso…
Telangiectasia in Systemic Sclerosis Is a Marker of Increased Disease Morbidity and Mortality: Analyses From the Australian Scleroderma Cohort Study.
This Australian retrospective cohort analysis of 1977 patients investigates and expands on correlates of telangiectasia in systemic sclerosis to determine whether this cutaneous sign is a potential surrogate marker for disease progression and prognosis. We found that pulmonary arterial hypertension…
Microvascular barrier - Transdermal and topical drug delivery in Raynaud's Phenomenon.
Raynaud Phenomenon (RP) is a peripheral vascular disease that results in episodes of vasospasm of the microcirculation of hands and feet, which causes ischemia, pain and functional deficiency. Traditional systemic treatments of RP, such as calcium channel blockers and phosphodiesterase type-5 inhibi…
The prevalence and incidence of Raynaud's in England, United Kingdom.
To estimate the prevalence and incidence in Raynaud's and its association with age, sex, ethnicity and region in England. The Clinical Practice Research Datalink Aurum database was used to identify individuals with Raynaud's from 1998 to 2023. The prevalence of Raynaud's in 2023 and incidence rates…
Phosphodiesterase-5 inhibitors, but not calcium channel blockers, improve peripheral vascular function in systemic sclerosis.
Systemic sclerosis (SSc) is a rare autoimmune disease associated with vasculopathy. Raynaud's phenomenon is a common symptom of SSc, and treatment guidelines support calcium channel blocker (CCB) and phosphodiesterase inhibitor-5 (PDE5i) as first- and second-line therapy, respectively. However, the…
Autoantibody associations in patients with early diffuse cutaneous systemic sclerosis: the prospective registry of early systemic sclerosis.
Anti-RNA-polymerase-III (ARA) and anti-topoisomerase-I (ATA) autoantibodies are associated with diffuse cutaneous SSc (dcSSc). ARA is associated with rapidly progressive skin thickening, scleroderma renal crisis (SRC), and gastric antral vascular ectasia, while ATA is associated with severe intersti…